PRM_PROMACTA_ONCOLOGY

Drug Novartis Pharma AG
Total Payments
$33,505
Transactions
15
Doctors
10
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $26,917 7 7
2019 $6,588 8 3

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $32,267 8 96.3%
Travel and Lodging $859.63 3 2.6%
Food and Beverage $378.26 4 1.1%

Top Doctors Receiving Payments for PRM_PROMACTA_ONCOLOGY

Doctor Specialty Location Total Records
, M.D Hematology & Oncology New York, NY $6,000 1
, MD Pediatric Hematology-Oncology Atlanta, GA $5,954 5
, MD DPHIL Internal Medicine Boston, MA $5,502 1
, MD Hematology & Oncology Boston, MA $3,930 1
, M.D Medical Oncology Houston, TX $3,275 1
, MD Hematology & Oncology Cleveland, OH $3,275 1
, M.D Hematology & Oncology Rochester, MN $2,475 1
, M.D Gynecologic Oncology Hilliard, OH $2,460 1
, MD Pediatrics New York, NY $556.79 2
, MD Internal Medicine Cleveland, OH $77.16 1

About PRM_PROMACTA_ONCOLOGY

PRM_PROMACTA_ONCOLOGY is a drug associated with $33,505 in payments to 10 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.

Payment data is available from 2019 to 2020. In 2020, $26,917 was paid across 7 transactions to 7 doctors.

The most common payment nature for PRM_PROMACTA_ONCOLOGY is "Consulting Fee" ($32,267, 96.3% of total).